sglt2 semaglutide Combining GLP-1 Receptor Agonists and Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy 🛑 2026 Type 2 Diabetes

ADA Standards of Care 2025) recommend that patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) (or high risk) should be on a GLP-1 RA with proven CV benefit (or an SGLT2 inhibitor) as part of their regimen, independent of A1c, because of the outcome benefits ( [9] ) ( [144] )

The discussion highlights overlooked contributors such as brain inflammation, low brain derived neurotrophic factor, and metabolic dysfunction, while previewing emerging treatments including transcranial magnetic stimulation, ketamine, psychedelic assisted therapy, and lifestyle and metabolic interventions

Week 12 assessment, if under 5% weight loss, discuss dose escalation

The bottom line The question pills or injections? is best answered by flipping it around: it is not about which form is superior, but about which molecule you need and how it best reaches your body

How about my brothers and me

Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use